Additional file 1: of Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

  • Meijian Guan (Contributor)
  • Jacob M. Keaton (Creator)
  • Latchezar Dimitrov (Creator)
  • Pamela J. Hicks (Creator)
  • Jianzhao Xu (Contributor)
  • Nicholette D. Palmer (Creator)
  • Lijun Ma (Contributor)
  • Swapan K. Das (Creator)
  • Yii Der Ida Chen (Contributor)
  • Josef Coresh (Creator)
  • Myriam Fornage (Creator)
  • Nora Franceschini (Creator)
  • Holly J. Kramer (Creator)
  • Carl D. Langefeld (Creator)
  • Josyf Mychaleckyj (Contributor)
  • Rulan S. Parekh (Contributor)
  • Wendy S. Post (Creator)
  • Laura Jarmila Rasmussen-Torvik (Creator)
  • Stephen S. Rich (Creator)
  • Jerome I. Rotter (Creator)
  • J. Sedor (Creator)
  • Denyse Thornley-Brown (Creator)
  • Adrienne Tin (Creator)
  • James G. Wilson (Creator)
  • Barry I. Freedman (Creator)
  • Donald W. Bowden (Creator)
  • Maggie C.Y. Ng (Creator)

Dataset

Description

Figure S1. QQ plot of GWAS results of T2D-ESKD vs. non-diabetic non-nephropathy controls under baseline model. Figure S2. P value comparisons between baseline, APOL1-negative, and APOL1-adjusted models. Table S1. Study description. Table S2. Genome-wide significant variants associated with T2D-ESKD at Stage 2 Meta-analysis. Table S3. Discrimination analysis in 2756 T2D-lacking nephropathy individuals and 6977 controls for genome-wide significant T2D-ESKD-associated variants in baseline mode. Table S4. Discrimination analysis in 2756 T2D-lacking nephropathy individuals and 6977 controls for genome-wide significant T2D-ESKD-associated variants in APOL1-negative model. Table S5. Results of APOL1-negative model for top associations identified in baseline model. Table S6. (Excel). Functional annotations of genome-wide significant T2D-ESKD variants and proxies in linkage disequilibrium (r2â >â 0.7). (ZIP 138 kb)
Date made available2019
Publisherfigshare

Cite this